Evaluating the effectiveness of vaccines for influenza and COVID-19 in preventing respiratory illnesses.
Official title: RFA-IP-22-004, Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
Funded at Kaiser Foundation Health Plan of Washington · NIH-10910860 · Data updated 2026-11-12
This study is looking at how well vaccines for flu and COVID-19 help keep people in Washington state from getting sick with respiratory illnesses, and it’s for anyone interested in understanding the benefits of these vaccines for our health.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kaiser Foundation Health Plan of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 30, 2022 |
| Project end | September 29, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,400,000 |
| NIH project number | 5U01IP001191-03 |
| Project ID | NIH-10910860 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living in Washington state who are at risk for respiratory illnesses, particularly those eligible for influenza and COVID-19 vaccinations.
✕Less likely to help
Patients who are not residents of Washington state or those who are not eligible for the vaccines being studied may not receive any benefit from this research.
What this research studies
This research investigates how well vaccines for influenza, SARS-CoV-2, and other respiratory viruses work in preventing acute respiratory illnesses in Washington state. Over the next five years, the study will collect and analyze data on vaccine effectiveness in real-world settings, particularly focusing on the impact of these vaccines on public health. By monitoring the incidence of respiratory illnesses and the effectiveness of vaccination programs, the research aims to provide valuable insights for policymakers and healthcare providers.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies that significantly reduce the burden of respiratory illnesses in the community.
How similar studies have gone: Previous studies have shown success in evaluating vaccine effectiveness for respiratory viruses, indicating that this approach is both relevant and necessary.
Where this research is happening
-
Kaiser Foundation Health Plan of Washington
Seattle, United States Active
Researchers
- Principal investigator: Wernli, Karen J — Kaiser Foundation Health Plan of Washington
- Study coordinator: Wernli, Karen J
Related research
Other NIH-funded projects on the same topics.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Burden and consequences of influenza, SARS-CoV-2 and other respiratory viruses among Indian adults
This grant aims to study how flu and COVID-19 and related respiratory infections affect Indian adults 18–60, including costs, outcomes, and vaccine uptake to inform health policy.
-
Leptin and fat cells: how obesity may worsen lung infections like COVID-19 and flu
A study explores how fat tissue and the leptin pathway might change the body's first lung defenses during respiratory infections in people who are obese or have diabetes.
-
Vaccine effectiveness in preventing respiratory illness in Washington state (2022–2027)
This project tests how well vaccines against flu, COVID-19, and other respiratory viruses protect people in Washington state from getting acutely ill.
-
Understanding flu and COVID-19 vaccine responses in adults
A Stanford-led effort studies how the flu and COVID-19 vaccines work in adults and how to make them work better for people, especially those with higher risk from underlying health conditions.
-
How flu, COVID-19, and other respiratory vaccines protect people in Washington from sudden respiratory illness
This project checks how well seasonal flu, COVID-19, and other respiratory vaccines prevent short-term respiratory illnesses in people living in Washington state.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.